Company Analysis
Sign in

Sarepta Therapeutics, Inc. (SRPT)

Nasdaq: SRPT · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 1997
Full chart Alerts Compare
Grade6.2
◀ Past 8.0● Present 5.6▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

177 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Sarepta Therapeutics, Inc.’s names, not what it holds today.

Patents granted
177
177 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 8 in 2024 and 6 in 2023
Applications published
253
26 of them in 2025
Names they are printed under
5
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals28
Biotechnology11
Organic fine chemistry8
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
SAREPTA THERAPEUTICS, INC. its own name
US, as the owner printed on each patent. 6 more under the same name are not counted (printed in GB)
123 granted
91 published
Sarepta Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
121 published
AVI BIOPHARMA, INC. a former name
US, as the owner printed on each patent
50 granted
40 published
Antivirals Inc. a former name
US, as the owner printed on each patent
4 granted
0 published
AVI BIOPHARMA, INC. a former name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,502,432Bicyclic peptide oligonucleotide conjugatesPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Aug 19, 202512,391,745Adeno-associated virus antibodies and fragments thereofBiotechnologySAREPTA THERAPEUTICS, INC.
Aug 5, 202512,377,150Exon skipping oligomer conjugates for muscular dystrophyPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Jul 29, 202512,370,261Chimeric peptides for antisense deliveryPharmaceuticalsSAREPTA THERAPEUTICS, INC.
May 13, 202512,297,219Phosphorodiamidate morpholino oligomersOrganic fine chemistrySAREPTA THERAPEUTICS, INC.
Apr 29, 202512,286,630Treatment methods for muscular dystrophyBiotechnologySAREPTA THERAPEUTICS, INC.
Mar 25, 202512,258,362Processes for preparing phosphorodiamidate morpholino oligomersOrganic fine chemistrySAREPTA THERAPEUTICS, INC.
Mar 4, 202512,239,715Peptide oligonucleotide conjugatesPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Dec 17, 202412,168,059Trimeric peptides for antisense deliveryBiotechnologySAREPTA THERAPEUTICS, INC.
Nov 12, 202412,139,709Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase genePharmaceuticalsSAREPTA THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387299DOSE PACKAGING SYSTEM FOR MEDICATION AND METHOD OF STORING DOSE THEREINMedical technologySarepta Therapeutics, Inc.
Dec 4, 20252025/0369016MUSCLE TROPIC RAAVPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Dec 4, 20252025/0367306CHIMERIC PEPTIDES FOR ANTISENSE DELIVERYPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Nov 27, 20252025/0360228TREATMENT OF GENETIC NEUROLOGICAL CONDITIONS WITH GENOMIC EDITINGBiotechnologySAREPTA THERAPEUTICS, INC.
Sep 18, 20252025/0290069EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHYBiotechnologySAREPTA THERAPEUTICS, INC.
Sep 4, 20252025/0276988PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERSOrganic fine chemistrySAREPTA THERAPEUTICS, INC.
Jul 31, 20252025/0241940MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHYPharmaceuticalsSarepta Therapeutics, Inc.
Jul 24, 20252025/0236869EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYPharmaceuticalsSAREPTA THERAPEUTICS, INC.
Jul 17, 20252025/0228954Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine LearningComputer technologySarepta Therapeutics, Inc.
Jun 19, 20252025/0195667PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER CONJUGATESBiotechnologySarepta Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 19 · Biotechnology 13 · Organic fine chemistry 3 · Computer technology 1 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SRPT · research, not advice